BackgroundThymic epithelial cell (TEC) microenvironments are essential for the
recruitment of T cell precursors from the bone marrow, as well as the
subsequent expansion and selection of thymocytes resulting in a mature
self-tolerant T cell repertoire. The molecular mechanisms, which control
both the initial development and subsequent maintenance of these critical
microenvironments, are poorly defined. Wnt signaling has been shown to be
important to the development of several epithelial tissues and organs.
Regulation of Wnt signaling has also been shown to impact both early
thymocyte and thymic epithelial development. However, early blocks in thymic
organogenesis or death of the mice have prevented analysis of a role of
canonical Wnt signaling in the maintenance of TECs in the postnatal
thymus.Methodology/Principal FindingsHere we demonstrate that tetracycline-regulated expression of the canonical
Wnt inhibitor DKK1 in TECs localized in both the cortex and medulla of adult
mice, results in rapid thymic degeneration characterized by a loss of
ΔNP63+ Foxn1+ and
Aire+ TECs, loss of K5K8DP TECs thought to represent
or contain an immature TEC progenitor, decreased TEC proliferation and the
development of cystic structures, similar to an aged thymus. Removal of DKK1
from DKK1-involuted mice results in full recovery, suggesting that canonical
Wnt signaling is required for the differentiation or proliferation of TEC
populations needed for maintenance of properly organized adult thymic
epithelial microenvironments.Conclusions/SignificanceTaken together, the results of this study demonstrate that canonical Wnt
signaling within TECs is required for the maintenance of epithelial
microenvironments in the postnatal thymus, possibly through effects on TEC
progenitor/stem cell populations. Downstream targets of Wnt signaling, which
are responsible for maintenance of these TEC progenitors may provide useful
targets for therapies aimed at counteracting age associated thymic
involution or the premature thymic degeneration associated with cancer
therapy and bone marrow transplants.